Literature DB >> 30348718

Prognostic Value of Thyroid Transcription Factor-1 Expression in Patients with Advanced Lung Adenocarcinoma.

Rolandas Zablockis1,2, Edvardas Žurauskas3,4, Edvardas Danila5,2, Vygantas Gruslys5,2.   

Abstract

BACKGROUND/AIM: The prognostic role of thyroid transcription factor-1 (TTF1) in advanced lung cancer is not clearly established. The present study aimed to evaluate the associations between clinicopathological characteristics, TTF1 expression, and overall survival (OS) of patients with advanced lung adenocarcinoma.
MATERIALS AND METHODS: One hundred and seventy-two patients were enrolled in this retrospective study. OS was assessed according to immunohistochemical TTF1 expression in lung adenocarcinoma tissue, age, gender, performance status (PS), smoking history and status, disease stage, tumor differentiation, epidermal growth factor receptor (EGFR) mutation and EGFR tyrosine kinase inhibitor (TKI) treatment status.
RESULTS: The OS time was longer (p<0.001) for patients with TTF1 expression than for patients without TTF1 expression (13.0 vs. 5.0 months, respectively). A multivariate analysis confirmed that worse PS [hazard ratio (HR)=2.13, p<0.001], poor histological differentiation (HR=2.02, p=0.001), wild-type EGFR status (HR=3.08, p<0.001) and negative TTF1 expression (HR=1.97, p=0.001) were independent predictors of worse prognosis.
CONCLUSION: TTF1 expression is an independent predictor of survival of patients with advanced lung adenocarcinoma. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Lung cancer; adenocarcinoma; pathology; prognostic factors

Mesh:

Substances:

Year:  2018        PMID: 30348718      PMCID: PMC6365745          DOI: 10.21873/invivo.11416

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  35 in total

Review 1.  Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care.

Authors:  Marco Maltoni; Augusto Caraceni; Cinzia Brunelli; Bert Broeckaert; Nicholas Christakis; Steffen Eychmueller; Paul Glare; Maria Nabal; Antonio Viganò; Philip Larkin; Franco De Conno; Geoffrey Hanks; Stein Kaasa
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

2.  EGFR mutation is specific for terminal respiratory unit type adenocarcinoma.

Authors:  Yasushi Yatabe; Takayuki Kosaka; Takashi Takahashi; Tetsuya Mitsudomi
Journal:  Am J Surg Pathol       Date:  2005-05       Impact factor: 6.394

3.  Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis.

Authors:  T Berghmans; M Paesmans; C Mascaux; B Martin; A-P Meert; A Haller; J-J Lafitte; J-P Sculier
Journal:  Ann Oncol       Date:  2006-09-15       Impact factor: 32.976

4.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

5.  Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma.

Authors:  Justine A Barletta; Sven Perner; A John Iafrate; Beow Y Yeap; Barbara A Weir; Laura A Johnson; Bruce E Johnson; Matthew Meyerson; Mark A Rubin; William D Travis; Massimo Loda; Lucian R Chirieac
Journal:  J Cell Mol Med       Date:  2009-08       Impact factor: 5.310

6.  Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis.

Authors:  G D Smith; B E Chadwick; C Willmore-Payne; J S Bentz
Journal:  J Clin Pathol       Date:  2007-10-01       Impact factor: 3.411

7.  Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study.

Authors:  Dongfeng Tan; Qiang Li; George Deeb; Nithyia Ramnath; Harry K Slocum; John Brooks; Richard Cheney; Sam Wiseman; Timothy Anderson; Gregory Loewen
Journal:  Hum Pathol       Date:  2003-06       Impact factor: 3.466

8.  Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung.

Authors:  Luke T Nordquist; George R Simon; Alan Cantor; W Michael Alberts; Gerold Bepler
Journal:  Chest       Date:  2004-08       Impact factor: 9.410

9.  Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma.

Authors:  Chien-Te Li; Magdalena Marek; Salih Z Guclu; Younseup Kim; Mohamed Meshref; Shukui Qin; Zbigniew Kadziola; Kurt Krejcy; Sedat Altug
Journal:  J Cancer       Date:  2011-01-11       Impact factor: 4.207

10.  Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung.

Authors:  F Barlési; D Pinot; A Legoffic; C Doddoli; B Chetaille; J-P Torre; P Astoul
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

View more
  1 in total

1.  LncRNA LINC00511 plays an oncogenic role in lung adenocarcinoma by regulating PKM2 expression via sponging miR-625-5p.

Authors:  Jinghui Xue; Fayan Zhang
Journal:  Thorac Cancer       Date:  2020-07-27       Impact factor: 3.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.